Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 17/20 | 0.50 |
| ▸ | F11 | P03951 | 3/20 | 0.50 |
| ▸ | TPSB2 | P20231 | 3/20 | 0.50 |
| ▸ | PLAU | P00749 | 2/20 | 0.50 |
| ▸ | PLG | P00747 | 1/20 | 0.50 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.50 |
| ▸ | F7 | P08709 | 1/20 | 0.50 |
| ▸ | SELL | P14151 | 1/20 | 0.46 |
| ▸ | SELP | P16109 | 1/20 | 0.46 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.40 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21562015 | 0.91 | CFD (0.46) | CFDF11TPSB2PLAUPLG | |
| SCHEMBL21438005 | 0.85 | CFD (0.64) | CFDF11TPSB2PLAUPLG | |
| SCHEMBL23656659 | 0.81 | CFD (0.50) | CFDF11TPSB2PLAUPLG | |
| SCHEMBL23656625 | 0.77 | CFD (0.50) | CFDF11TPSB2PLAUPLG | |
| SCHEMBL21438567 | 0.77 | CFD (0.62) | CFDF11TPSB2PLAUPLG | |
| SCHEMBL23656559 | 0.76 | CFD (0.51) | CFDF11TPSB2PLAUPLG | |
| SCHEMBL21437800 | 0.76 | CFD (0.52) | CFDF11TPSB2PLAUPLG | |
| SCHEMBL29634113 | 0.76 | CFD (0.52) | CFDF11TPSB2PLAUPLG | |
| SCHEMBL23218898 | 0.75 | CFD (0.57) | CFDF11TPSB2PLAUPLG | |
| SCHEMBL29852513 | 0.75 | CFD (0.57) | CFDF11TPSB2PLAUPLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021458-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20190345135-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021458-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | C9, C5, C1QBP | CFD 17/4885F11 216/4885TPSB2 169/4885 |
| US-20190345135-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | C9, C5, C1QBP | CFD 17/4885F11 216/4885TPSB2 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.